24 September 2025
\n \n \n \nTwo research teams in the Nuffield Department of Medicine have been selected for the final stages of the Cancer Grand Challenges. This includes Professor Xin Lu at Ludwig Oxford in the Cancer Antibody Atlas team and Dr Ricardo Fernandes at the CAMS Oxford Institute as a co-investigator in a team led by the Weizmann Institute.
\n \n\n \n \n16 September 2025
\n \n \n \nDr. Yi-Ling Chen, COI Career Development Fellow, awarded a prestigious ERC Starting Grant to Investigate the Role of CD1c-reactive T Cells in Post-streptococcal Disease. The ERC Starting Grant supports early-career researchers with 2-7 years of experience since completion of their PhD, providing up to \u20ac1.5 million over five years to establish independent research teams and pursue high-risk, high-reward science.
\n \n\n \n \n2 September 2025
\n \n \n \nTwo new papers from scientists in the Nuffield Department of Medicine and other University of Oxford institutions have shown how the immune system reacts differently depending on the length of interval between vaccine doses.
\n \n\n \n \n28 August 2025
\n \n \n \nA new study published in Nature reveals that the mechanical environment surrounding a tumour can cause cancer cells to change their behaviour, triggering a switch from rapid growth to a more invasive, drug-resistant state.
\n \n\n \n \n27 August 2025
\n \n \n \nA research team in the Nuffield Department of Medicine has been awarded access to one of the UK\u2019s most powerful AI supercomputing facilities to advance cancer vaccine research.
\n \n\n \n \n22 August 2025
\n \n \n \nResearchers from the Oxford University Clinical Research Unit (OUCRU) have played a leading role in developing the world\u2019s first international clinical practice guideline for tuberculous meningitis, now published in The Lancet Infectious Diseases.
\n \n\n \n \n21 August 2025
\n \n \n \nFor the first time, a team of researchers have identified a new genetic link to pain, offering a promising drug target to alleviate chronic pain.
\n \n\n \n \n20 August 2025
\n \n \n \nResearchers in the Big Data Institute at the University of Oxford, together with MS experts from ten leading institutions across the world and drug developers from Novartis and Roche, have collaborated to develop an artificial intelligence (AI) model for reclassifying the progression of multiple sclerosis (MS). This model is based on the largest collection of clinical trial data (Novartis-Oxford MS dataset) from people living with MS.
\n \n\n \n \n19 August 2025
\n \n \n \nResearchers at Ludwig Cancer Research Oxford have recently published their findings exploring a new role for platelets, potentially offering a new way to improve cancer detection.
\n \n\n \n \n14 August 2025
\n \n \n \nA multi-disciplinary study by KEMRI-Wellcome Trust, Harnessing Innovation in Global Health for Quality Care (HIGH-Q), has revealed how workforce issues influence the quality of care in newborn units. The research highlighted the effect of severe nurse staffing shortages in Kenyan hospitals as a major obstacle to providing quality care for newborns.
\n \n\n \n \n12 August 2025
\n \n \n \nResearchers at NDM\u2019s Centre for Human Genetics have discovered that cell-free DNA builds up in the blood of patients with sepsis because of impaired liver clearance. These findings show that investigating cell-free DNA could be a powerful tool for monitoring what happens in the body during sepsis.
\n \n\n \n \n8 August 2025
\n \n \n \nResearchers from the UK and Madagascar, in collaboration with Madagascar\u2019s health services and national plague programme, have conducted the world\u2019s first rigorous clinical trial of treatments for bubonic plague.
\n \n\n \n \n7 August 2025
\n \n \n \nIn a collaborative new study, researchers have developed the first mathematically supported cellular map of lung tissue in idiopathic pulmonary fibrosis and uncovered key immune cell interactions that could explain why lungs fail to repair in this deadly disease with no known cure.
\n \n\n \n \n6 August 2025
\n \n \n \nA new paper conducted by the Infectious Disease Data Observatory and the World Health Organization has revealed major gaps in research on noma, a severe and often fatal oral disease affecting children in low-resource settings. The review analysed 366 studies to provide a comprehensive foundation for future research and policy action.
\n \n\n \n \n5 August 2025
\n \n \n \nHosted by the Centre for Genomic Pathogen Surveillance at PSI, the new Centre will support efforts to tackle one of the most pressing global health challenges of our time - antimicrobial resistance.
\n \n\n \n \n30 July 2025
\n \n \n \nIn a new study from Tao Dong\u2019s Group, researchers have found a way to harness strong immune responses in people with early-stage breast cancer \u2013 opening up new treatment options for those in more advanced stages.
\n \n\n \n \n29 July 2025
\n \n \n \nOUCRU and the Health Strategy and Policy Institute have signed a Memorandum of Understanding to promote joint research and evidence-based health policy. The agreement marks a significant step toward a long-term interdisciplinary collaboration.
\n \n\n \n \n25 July 2025
\n \n \n \nHis Royal Highness the Duke of Gloucester visited the University of Oxford this week to tour two of its leading medical research centres: the Clinical BioManufacturing Facility (CBF) and the laboratories of the Oxford Vaccine Group (OVG) and Pandemic Sciences Institute (PSI), located on the University\u2019s Old Road Campus.
\n \n\n \n \n24 July 2025
\n \n \n \nA collaborative new study involving KEMRI-Wellcome Trust researchers has highlighted a new way to control malaria transmission. The study found that ivermectin, a drug normally used for neglected tropical diseases, led to a 26% reduction in new malaria infections among children aged 5-15.
\n \n\n \n \n11 July 2025
\n \n \n \nIn a new study from NDM\u2019s Division of Structural Biology, researchers have found out how HIV-1 breaches the cell\u2019s most guarded barrier, revealing the determinants that control the nuclear import of HIV-1.
\n \n\n \n \n